# Supply and Procurement Strategy 2016-2020

**Priorities**
- Healthy Markets
- Long-term View
- Innovation

**Scope**
- Gavi supported countries (including transitioning countries)
- Vaccines for Board-approved antigens
- Other immunisation products (focus on cold chain equipment)

**Objectives**

<table>
<thead>
<tr>
<th>Create Healthy Markets in Support of Gavi Countries' Immunisation Needs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sufficient and secure supply</td>
</tr>
</tbody>
</table>

**Enablers**

**Actors**

- Countries as Customers
- Market shaping intermediaries
- Industry

**Approaches and Tools**

- Roadmaps
- Coordination and accountability
- Data collection and analytics
- Forecasting (strategic and operational)
- Healthy Markets Framework
- Tailored procurement
- Manufacturer engagement

**Monitoring and Evaluation**

- Outcome Indicators
- Process indicators
- Market Shaping externalities
- Evaluation of strategy outcomes and impact

**Outcomes by 2020**

- 11 vaccine markets have sufficient and uninterrupted supply
- Decrease in Weighted Average Price (per child) to fully immunise with pentavalent, pneumococcal, and rotavirus vaccines
- 10 new products procured by Gavi with improved characteristics

**6 Vaccine Markets Have Moderate or High 'Healthy Market Dynamics'**